552 related articles for article (PubMed ID: 18462098)
1. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy.
Wolter DJ; Acquazzino D; Goering RV; Sammut P; Khalaf N; Hanson ND
Clin Infect Dis; 2008 Jun; 46(12):e137-41. PubMed ID: 18462098
[TBL] [Abstract][Full Text] [Related]
2. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Chinese hospitals.
Wang J; Zhou JY; Qu TT; Shen P; Wei ZQ; Yu YS; Li LJ
Int J Antimicrob Agents; 2010 May; 35(5):486-91. PubMed ID: 20185276
[TBL] [Abstract][Full Text] [Related]
3. A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
Evans JC; Segal H
Antimicrob Agents Chemother; 2007 Oct; 51(10):3776-7. PubMed ID: 17682099
[No Abstract] [Full Text] [Related]
4. ISPa46, a novel insertion sequence in the oprD porin gene of an imipenem-resistant Pseudomonas aeruginosa isolate from a cystic fibrosis patient in Marseille, France.
Diene SM; L'homme T; Bellulo S; Stremler N; Dubus JC; Mely L; Leroy S; Degand N; Rolain JM
Int J Antimicrob Agents; 2013 Sep; 42(3):268-71. PubMed ID: 23880169
[TBL] [Abstract][Full Text] [Related]
5. Classification of OprD sequence and correlation with antimicrobial activity of carbapenem agents in Pseudomonas aeruginosa clinical isolates collected in Japan.
Sanbongi Y; Shimizu A; Suzuki T; Nagaso H; Ida T; Maebashi K; Gotoh N
Microbiol Immunol; 2009 Jul; 53(7):361-7. PubMed ID: 19563394
[TBL] [Abstract][Full Text] [Related]
6. Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype.
Wolter DJ; Black JA; Lister PD; Hanson ND
J Antimicrob Chemother; 2009 Aug; 64(2):294-300. PubMed ID: 19468029
[TBL] [Abstract][Full Text] [Related]
7. Pseudomonas aeruginosa infection in cystic fibrosis caused by an epidemic metallo-β-lactamase-producing clone with a heterogeneous carbapenem resistance phenotype.
Pollini S; Fiscarelli E; Mugnaioli C; Di Pilato V; Ricciotti G; Neri AS; Rossolini GM
Clin Microbiol Infect; 2011 Aug; 17(8):1272-5. PubMed ID: 21375657
[TBL] [Abstract][Full Text] [Related]
8. A highly carbapenem-resistant Pseudomonas aeruginosa isolate with a novel blaVIM-4/blaP1b integron overexpresses two efflux pumps and lacks OprD.
Maniati M; Ikonomidis A; Mantzana P; Daponte A; Maniatis AN; Pournaras S
J Antimicrob Chemother; 2007 Jul; 60(1):132-5. PubMed ID: 17483142
[TBL] [Abstract][Full Text] [Related]
9. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase.
Gales AC; Menezes LC; Silbert S; Sader HS
J Antimicrob Chemother; 2003 Oct; 52(4):699-702. PubMed ID: 12951331
[TBL] [Abstract][Full Text] [Related]
10. Emergence of carbapenem-hydrolysing metallo-beta-lactamase VIM-1 in Pseudomonas aeruginosa isolates in France.
Corvec S; Poirel L; Decousser JW; Allouch PY; Drugeon H; Nordmann P
Clin Microbiol Infect; 2006 Sep; 12(9):941-2. PubMed ID: 16882306
[No Abstract] [Full Text] [Related]
11. Carbapenem resistance in cystic fibrosis strains of Pseudomonas aeruginosa as a result of amino acid substitutions in porin OprD.
Richardot C; Plésiat P; Fournier D; Monlezun L; Broutin I; Llanes C
Int J Antimicrob Agents; 2015 May; 45(5):529-32. PubMed ID: 25735764
[TBL] [Abstract][Full Text] [Related]
12. A carbapenem-susceptible Pseudomonas aeruginosa strain carrying the bla(SPM) gene.
Pellegrino FL; Casali N; Nouér SA; Riley LW; Moreira BM
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):214-6. PubMed ID: 18308497
[TBL] [Abstract][Full Text] [Related]
13. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
El Amin N; Giske CG; Jalal S; Keijser B; Kronvall G; Wretlind B
APMIS; 2005 Mar; 113(3):187-96. PubMed ID: 15799762
[TBL] [Abstract][Full Text] [Related]
14. Stable carbapenem susceptibility rates among multidrug-resistant Acinetobacter spp. strains in a setting of high prevalence of carbapenem-resistant Pseudomonas aeruginosa.
Zavascki AP; Soares FC; Superti SV; Silbert S; Silva FM; Barth AL
Int J Antimicrob Agents; 2007 Aug; 30(2):187-9. PubMed ID: 17452093
[No Abstract] [Full Text] [Related]
15. Efflux system overexpression and decreased OprD contribute to the carbapenem heterogeneity in Pseudomonas aeruginosa.
Ikonomidis A; Tsakris A; Kantzanou M; Spanakis N; Maniatis AN; Pournaras S
FEMS Microbiol Lett; 2008 Feb; 279(1):36-9. PubMed ID: 18070070
[TBL] [Abstract][Full Text] [Related]
16. Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified?
Macdonald D; Cuthbertson L; Doherty C; Campana S; Ravenni N; Taccetti G; Govan JR
J Antimicrob Chemother; 2010 Nov; 65(11):2373-5. PubMed ID: 20837573
[TBL] [Abstract][Full Text] [Related]
17. Metallo-beta-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in Brazil.
Viana Vieira V; Lourenço da Fonseca E; Paulo Vincente AC
Clin Microbiol Infect; 2005 Nov; 11(11):937. PubMed ID: 16216114
[No Abstract] [Full Text] [Related]
18. Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem.
Eagye KJ; Nicolau DP
J Antimicrob Chemother; 2011 Jun; 66(6):1392-5. PubMed ID: 21459897
[TBL] [Abstract][Full Text] [Related]
19. Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa.
Shigemi A; Matsumoto K; Yaji K; Shimodozono Y; Takeda Y; Miyanohara H; Kawamura H; Orita M; Tokuda K; Nishi J; Yamada K
Int J Antimicrob Agents; 2009 Dec; 34(6):589-91. PubMed ID: 19748231
[TBL] [Abstract][Full Text] [Related]
20. Genetic heterogeneity of carbapenem-resistant Pseudomonas aeruginosa isolates co-infecting the cerebrospinal fluid of a pediatric patient.
Gaspar EB; Neves PR; Levy CE; Mamizuka EM; Lincopan N
Diagn Microbiol Infect Dis; 2011 Aug; 70(4):568-70. PubMed ID: 21429695
[No Abstract] [Full Text] [Related]
[Next] [New Search]
